Executive Summary
NASA's $2.95B obligation to Caltech for JPL operations (with $2.43B outlayed and $3.15B potential including options) through 2028 confirms stable, non-competitive funding for space R&D including Europa Clipper, but as a nonprofit FFRDC, offers no direct equity exposure. This sole contract in the period highlights concentrated reliance on JPL for critical missions amid a 10-year term.
Investors should monitor task order issuances and option exercises for indirect sector signals.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior All NASA Contracts digest from March 20, 2026.
Investment Signals (2)
- Stable JPL Funding Locked In (HIGH)▲
$2.95B obligation with $2.43B outlayed underscores NASA's commitment to Caltech/JPL for space science through 2028.
- Task Order Variability (MEDIUM)▲
Delivery order structure exposes value to future NASA task orders beyond base funding.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
10-year term to 2028-09-30 vulnerable to NASA funding shifts or delayed task orders.
Opportunities (1)
- ◆
$202M in unexercised options elevates potential to $3.15B; signals scope for expanded space R&D work.
Sector Themes (1)
- ◆
Single $2.95B non-competed award to Caltech/JPL reflects heavy reliance on nonprofits for core space science R&D.
Watch List (1)
- 👁
{"entity"=>"Caltech/JPL Contract", "reason"=>"100% of period value; tracks NASA space priorities amid $2.43B outlayed.", "trigger"=>"Option exercises exceeding $200M or funding revisions"}
Get daily alerts with 2 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: All NASA Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals